Clinical trials: Disease, Chronic
Hepatitis C, Chronic
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
This study is an open-label, multi-center trial to evaluate the novel 2-drug regimen of uprifosbuvir (MK-3682) 450 mg and ruzasvir (MK-8408) 60 mg in participants with chronic hepatitis C virus (HCV) genotype (GT)1, GT2, GT3…
- Trial name
- NCT02759315
- Testing
- Uprifosbuvir 450 mg, Ruzasvir 60 mg
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia (CLL)
Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia
This study consists of 2 parts: Phase 1b and Phase 2. Phase 1b will evaluate the safety and tolerability of the combination of idelallisib with the anti-CD37 monoclonal antibody BI 836826 in participants with relapsed/refractory…
- Trial name
- NCT02538614
- Testing
- Idelalisib, BI 836826
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Gilead Sciences
Chronic Kidney Disease
Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease
The objective of this study is to assess the long-term safety and efficacy of bixalomer under post-marketed setting.
- Trial name
- NCT02805348
- Testing
- Bixalomer
- Where
- 14 sites in Japan
- Volunteers
- 144 people
- Sponsor
- Astellas Pharma Inc
Progressive Multiple Sclerosis
A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Primary Objective: To assess the safety and tolerability of GZ402668 after ascending single intravenous (IV) and subcutaneous (SC) doses in men and women with progressive multiple sclerosis.
- Trial name
- NCT02282826
- Testing
- GZ402668, acyclovir
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Kidney Disease
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)
The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 100 mg, 200 mg or 500 mg in subjects with Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).
- Trial name
- NCT01469078
- Testing
- Monofer®
- Volunteers
- 18 people
- Sponsor
- Pharmacosmos A/S
Leukemia, Lymphocytic, Chronic, B-Cell
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL)…
- Trial name
- QOLIBRI (NCT06299540)
- Testing
- Individual Physical Activity Intervention (IPAI), Ibrutinib
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Janssen Cilag S.A.S.
NALP3 Mutation
Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms
This study will investigate the clinical efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ACZ885, administered intravenously and subcutaneously to patients with NALP3 mutations whose clinical symptoms are…
- Trial name
- NCT00487708
- Testing
- canakinumab
- Where
- 10 sites in France, Germany and 3 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Plaque-type Psoriasis
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- FEATURE (NCT01555125)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
End Stage Renal Disease
Carry Life@ UF System Clinical Study
The Carry Life UF system performs peritoneal ultrafiltration by adding glucose to the low glucose strength (1.36%) peritoneal dialysis fluid which has been instilled into the peritoneal cavity prior to the connection of the…
- Trial name
- NCT05874804
- Testing
- Carry Life UF, 2.27% glucose peritoneal dialysis dwell
- Where
- 11 sites in Italy, Sweden and 1 more
- Volunteers
- 28 people
- Sponsor
- Triomed AB
Wounds and Injuries, Burns
ACTICOAT™ for the Treatment of Burns and Chronic Wounds
The aim of the study is to evaluate participant reported quality of life, safety, and overall performance with ACTICOAT in a clinical setting.
- Conditions
- Wounds and Injuries, Burns, Pressure Ulcer, Foot Ulcer
- Trial name
- NCT02852148
- Testing
- ACTICOAT
- Where
- 3 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- Smith & Nephew, Inc.
Anemia, Iron Deficiencies
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults.
This study is testing CTX001 for certain conditions where the body does not have enough available iron or has difficulty storing or moving iron properly.
- Conditions
- Anemia, Iron Deficiencies, Chronic Kidney Disease
- Trial name
- NCT07577817
- Testing
- CTX001 With and Without Iron, CTX001 With Iron, CTX001 Multiple Dose
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Cajal Therapeutics Inc.
Anemia of Chronic Kidney Disease
Project Aura: Co-design of a Home-based Monitoring Service
Co-design of a home-based haemoglobin monitoring system with participants with anaemia of chronic kidney disease.
- Trial name
- NCT04112615
- Testing
- Blood measurement
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Entia Ltd
Secondary Hyperparathyroidism, End-Stage Renal Disease
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
The objective of this study was to observe the safety of paricalcitol utilization in pediatric participants (ages 0 to 16 years old) being treated for secondary hyperparathyroidism (SHPT).
- Trial name
- NCT01134315
- Testing
- Paricalcitol, Calcitriol
- Where
- 18 sites in United States
- Volunteers
- 61 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson Disease
A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)
This is a two part study to compare the PK of preladenant administered to participants with CRI to the PK of preladenant administered to healthy participants.
- Trial name
- NCT01323855
- Testing
- Preladenant
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Renal Insufficiency
An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
The purpose of the study is to provide pertinent information to enable decisions regarding the developability of LHW090 for use in patients with chronic renal insufficiency, including a comparison of the potential risk-benefit…
- Trial name
- NCT01846468
- Testing
- LHW090
- Where
- 2 sites in United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism
The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of selective Vitamin D Receptor Activator's as it is prescribed in the normal clinical setting and according…
- Trial name
- NCT01149291
- Where
- 22 sites in Turkey (Türkiye)
- Volunteers
- 511 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
B-Cell Chronic Lymphocytic Leukemia
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
This multicenter, double-blind, randomized, placebo-controlled study will evaluate the safety of a single infusion of tocilizumab versus placebo, administered in addition to standard premedications (antipyretic, antihistamine…
- Trial name
- NCT02336048
- Testing
- Chlorambucil, Obinutuzumab, Standard Premedication
- Where
- 14 sites in Israel, Italy and 3 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Pulmonary Disease, Chronic Obstructive
Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients
Study compares the efficacy and safety of tiotropium + a beta agonist (procaterol) vs. tiotropium alone among patients with moderate chronic obstructive pulmonary disease
- Trial name
- NCT00394485
- Testing
- Procaterol, Tiotropium
- Where
- Philippines
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical, Inc., Philippines
Heart Failure
Pilot Study for First Clinical Use of sc2Wear Furosemide Combination Product
The proposed pilot study aims to gain experience with the first clinical use of the to-be marketed drug-device combination product, the sc2Wear Furosemide Combination Product and to assess methods and procedures for evaluation of…
- Trial name
- NCT02804035
- Testing
- sc2Wear Furosemide
- Volunteers
- 27 people
- Sponsor
- scPharmaceuticals, Inc.
Chronic Hepatitis C
4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C
The purpose of this study is to determine if taking nitazoxanide alone for 4 weeks followed by 36 weeks of nitazoxanide plus peginterferon is superior to peginterferon plus ribavirin (standard of care) for 48 weeks.
- Trial name
- NCT00763568
- Testing
- Nitazoxanide, Peginterferon alfa-2a
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Romark Laboratories L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.